Baker Bros. Advisors LP Mirati Therapeutics, Inc. Transaction History

Baker Bros. Advisors LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$41.99 - $62.38 $114 Million - $169 Million	2,711,656 Added 192.35%	4,121,440 $242 Million
Q1 2020 May 15, 2020	BUY	$69.78 - $116.21 $7.16 Million - $11.9 Million	102,564 Added 7.85%	1,409,784 $108 Million
Q3 2019 Nov 14, 2019	SELL	$77.91 - $109.6 $94 Million - $132 Million	-1,206,242 Reduced 47.99%	1,307,220 $102 Million
Q2 2018 Aug 14, 2018	SELL	$26.05 - $52.4 $937,773 - $1.89 Million	-35,999 Reduced 1.41%	2,513,462 $124 Million
Q4 2017 Feb 14, 2018	BUY	$12.65 - $19.0 $3.55 Million - $5.32 Million	280,263 Added 12.35%	2,549,461 $46.5 Million
Q3 2017 Nov 14, 2017	BUY	$4.7 - $11.7 $10.7 Million - $26.5 Million	2,269,198	2,269,198 $26.5 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.